Lipoprotein(a) level as a predictor of cardiovascular disease and small apoliprotein(a) isoforms in dialysis patients: Assay-related differences are important

Clinica Chimica Acta

Volumn 397, Issue 1-2, 2008, Pages 36-41

  Longenecker, J Craig ^a,b   Coresh, Josef ^a   Klag, Michael J ^a   Powe, Neil R ^a   Fink, Nancy E ^a   Marcovina, Santica M ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b KUWAIT UNIVERSITY   (Kuwait)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Apolipoprotein(a) isoforms size; Cardiovascular disease; Dialysis; Lipoprotein(a); Sensitivity; Specificity

Indexed keywords

APOLIPOPROTEIN A; LIPOPROTEIN A;

ARTICLE; ASSAY; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; DIALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TURBIDIMETRY; WESTERN BLOTTING;

APOLIPOPROTEINS A; CARDIOVASCULAR DISEASES; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; PROTEIN ISOFORMS; RENAL DIALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 51249124857     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2008.07.012     Document Type: Article

References (21)

1. Kronenberg F., Neyer U., Lhotta K., et al. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol 10 (1999) 1027-1036
2. Koch M., Kutkuhn B., Trenkwalder E., et al. Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. J Am Soc Nephrol 8 (1997) 1889-1898
3. Longenecker J.C., Klag M.J., Marcovina S.M., et al. Small apolipoprotein(a) size predicts mortality in end-stage renal disease: the CHOICE study. Circulation 106 (2002) 2812-2818
4. Longenecker J.C., Klag M.J., Marcovina S.M., et al. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. J Am Soc Nephrol 16 (2005) 1794-1802
5. Marcovina S.M., Koschinsky M.L., Albers J.J., and Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin Chem 49 (2003) 1785-1796
6. Marcovina S.M., Albers J.J., Scanu A.M., et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem 46 (2000) 1956-1967
7. Marcovina S.M., Albers J.J., Gabel B., Koschinsky M.L., and Gaur V.P. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem 41 (1995) 246-255
8. Dembinski T., Nixon P., Shen G., Mymin D., and Choy P.C. Evaluation of a new apolipoprotein(a) isoform-independent assay for serum Lipoprotein(a). Mol Cell Biochem 207 (2000) 149-155
9. Auguet T., Senti M., Rubies-Prat J., et al. Serum lipoprotein(a) concentration in patients with chronic renal failure receiving haemodialysis: influence of apolipoprotein (a) genetic polymorphism. Nephrol Dial Transplant 8 (1993) 1099-1103
10. Kronenberg F., Konig P., Neyer U., et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 6 (1995) 110-120
11. Marcovina S.M., Hobbs H.H., and Albers J.J. Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: basis for a standardized isoform nomenclature. Clin Chem 42 (1996) 436-439
12. Lackner C., Boerwinkle E., Leffert C.C., Rahmig T., and Hobbs H.H. Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis [published erratum appears in J Clin Invest 1991 Aug;88(2):723]. J Clin Invest 87 (1991) 2153-2161
13. Longenecker J.C., Coresh J., Marcovina S.M., et al. Lipoprotein(a) and prevalent cardiovascular disease in a dialysis population: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) study. Am J Kidney Dis 42 (2003) 108-116
14. United States Renal Data System, USRDS 1999 Annual Data Report. Bethesda, MD: The National Institutes of Health, NIDDK, 1999.
15. Miles L.A., Fless G.M., Levin E.G., Scanu A.M., and Plow E.F. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 339 (1989) 301-303
16. Edelberg J.M., Gonzalez-Gronow M., and Pizzo S.V. Lipoprotein a inhibits streptokinase-mediated activation of human plasminogen. Biochemistry 28 (1989) 2370-2374
17. Koschinsky M.L., and Marcovina S.M. Lipoprotein(a): structural implications for pathophysiology. Int J Clin Lab Res 27 (1997) 14-23
18. Hervio L., Girard-Globa A., Durlach V., and Angles-Cano E. The antifibrinolytic effect of lipoprotein(a) in heterozygous subjects is modulated by the relative concentration of each of the apolipoprotein(a) isoforms and their affinity for fibrin. Eur J Clin Invest 26 (1996) 411-417
19. Kronenberg F., Kronenberg M.F., Kiechl S., et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation 100 (1999) 1154-1160
20. Paultre F., Pearson T.A., Weil H.F., et al. High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men. Arterioscler Thromb Vasc Biol 20 (2000) 2619-2624
21. Rifai N., Ma J., Sacks F.M., et al. Apolipoprotein(a) Size and Lipoprotein(a) Concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: the physicians' health study. Clin Chem 50 (2004) 1364-1371